
|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Becoming a Partner of Choice and Evaluating Prospective Alliances
Author(s)Jan Heybroek, David Wallis
by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.
Advertisement
Articles in this issue
almost 23 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counseloralmost 23 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechalmost 23 years ago
Survival Strategies: Keeping Tabs on Trainingalmost 23 years ago
Biotech World: Contract Manufacturing: Diversity in the European Marketplacealmost 23 years ago
Outsourcing Outlook: Contract Services' Crystal Ballalmost 2023 years ago
Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: DisinfectionNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
2
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
3
How New ADC Modalities Backed by Samsung Could Shape Solid Tumor Treatment
4
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
5





